Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients

Last updated: August 14, 2021
Sponsor: Optall Vision
Overall Status: Active - Recruiting

Phase

1

Condition

Presbyopia

Treatment

N/A

Clinical Study ID

NCT05001243
PBOCP3
  • Ages 40-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound compared to Pilocarpine and Brimonidine to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy
  • Presbyopic
  • 40 - 59 years

Exclusion

Exclusion Criteria:

  • Diabetics
  • Previous eye surgery
  • Previous eye disease
  • > 0.50 myopia
  • > 1.5 hyperopia or astigmatism

Study Design

Total Participants: 11
Study Start date:
August 10, 2021
Estimated Completion Date:
September 10, 2021

Study Description

To determine the safety and efficacy of a novel pharmacological compound of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) to improve uncorrected near vision in healthy presbyopic patients compared to Pilocarpine and Brimonidine one hour after binocular instillation.

Connect with a study center

  • Optall Vision

    Mexico City, 01090
    Mexico

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.